D-0040-2027 Class II Ongoing
FDA drug recall D-0040-2027 was initiated by Houston Rx LLC on Sep 25, 2026 and is designated Class II. Reason for recall: Lack of assurance of sterility. The recall status is ongoing. Affected quantity: 64 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Oct 21, 2026
- Initiation Date
- Sep 25, 2026
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 64 vials
Product description
Tirzepatide/Niacinamide 2mL vial (40 MG per Vial) Inj 20mg/2mg/mL, RX Only, Houston RX LLC, 15430 Vantage Parkway E STE 220, Houston, TX 77032.
Reason for recall
Lack of assurance of sterility.
Distribution pattern
Nationwide in the USA.
Code information
Lot# TZN-080326-20/2-2, Beyond Use Date: 12/01/2026.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0040-2027
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026